China Resources Pharma Highlights Strong First-Quarter Performance at Dong-E-E-Jiao

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.

China Resources Pharmaceutical Group has disclosed the latest unaudited quarterly figures of its controlled subsidiary Dong-E-E-Jiao, a Shenzhen-listed Chinese medicine producer, highlighting the unit’s growing scale and strong balance sheet. The group effectively controls about 23.50% of Dong-E-E-Jiao, which is treated as a subsidiary in its consolidated accounts, providing investors with exposure to the Chinese traditional healthcare segment.

For the three months ended 31 March 2026, Dong-E-E-Jiao reported revenue of RMB1.81 billion, up from RMB1.72 billion a year earlier, and net profit of RMB454.8 million, compared with RMB424.6 million, alongside a sharp rise in cash and cash equivalents and lower total liabilities. The unaudited figures, prepared under PRC GAAP and subject to possible adjustments, signal improved profitability and liquidity at the subsidiary level, but the company cautioned that these numbers cover only Dong-E-E-Jiao and do not present a full picture of China Resources Pharmaceutical Group’s overall financial position, urging shareholders to exercise care when trading its shares.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated healthcare conglomerate with interests across the pharmaceutical value chain, including manufacturing, distribution, and retail of medicines and health products. Through its controlled subsidiary Dong-E-E-Jiao, a Shenzhen-listed company, it also participates in China’s traditional Chinese medicine and tonic health products market.

Average Trading Volume: 18,740,562

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$36.69B

For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.